Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 19/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| -2.43% | -7.34% | +36.10% | +58.44% | 62.23B | |
| +0.61% | +1.10% | +11.79% | +70.22% | 54.92B | |
| +0.62% | +2.74% | +17.68% | +103.81% | 55.26B | |
| +1.61% | -4.02% | +21.31% | +37.87% | 42.59B | |
| -1.74% | -4.28% | +14.34% | +95.00% | 41.08B | |
| +3.22% | +5.62% | +230.10% | +818.35% | 40.33B | |
| +0.57% | +25.47% | +102.34% | +88.40% | 33.12B | |
| -1.09% | -0.05% | +13.55% | +45.35% | 32.61B | |
| -4.46% | +11.90% | -44.92% | +317.59% | 23.98B | |
| Average | -0.24% | +3.75% | +44.70% | +181.67% | 42.9B | |
| Weighted average by Cap. | -0.19% | +2.11% | +45.07% | +165.17% |
Employees
355
